Rockwell Medical, Inc. (Nasdaq: RMTI) Regains Compliance With Nasdaq $1 Bid Rule
Rhea-AI Filing Summary
Rockwell Medical, Inc. reported that it has received notice from Nasdaq that the company has regained compliance with the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The shares maintained a closing bid of at least $1.00 from July 1, 2026 through July 15, 2026, and Nasdaq has closed the compliance matter. The company states it is now in full compliance with all Nasdaq continued listing requirements, and its common stock remains listed and traded under the ticker RMTI.
Rockwell Medical is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide, focused on supporting patients with end-stage kidney disease.
Positive
- Rockwell Medical has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), and Nasdaq has closed the matter while the company's common stock continues to trade on the Nasdaq Capital Market under the ticker RMTI.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Minimum bid price requirement: $1.00 per share
Compliance period: July 1, 2026 to July 15, 2026
Great Place to Work certification: 2023-2026
+1 more
4 metrics
Minimum bid price requirement
$1.00 per share
Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market
Compliance period
July 1, 2026 to July 15, 2026
Period during which shares maintained a minimum closing bid price of $1.00 or greater
Great Place to Work certification
2023-2026
Certified as a Great Place to Work four years in a row from 2023 to 2026
Fortune Best Workplaces recognition
2024 and 2025
Named Fortune Best Workplaces in Manufacturing & Production in 2024 and 2025
Key Terms
minimum bid price requirement, Nasdaq Listing Rule 5550(a)(2), continued listing requirements, hemodialysis, +1 more
5 terms
minimum bid price requirement regulatory
"regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2)"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(a)(2) regulatory
"minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2)"
continued listing requirements regulatory
"now in full compliance with all Nasdaq continued listing requirements"
Rules a stock exchange sets that a publicly traded company must keep meeting to stay listed and tradable on that exchange, such as minimum share price, market value, timely financial reports, and basic governance practices. Like a club’s membership rules, they matter because falling short can lead to warnings, penalties or removal from the exchange, which can cut liquidity, hurt share value and increase the risk for investors.
hemodialysis medical
"distributes a portfolio of hemodialysis products to dialysis providers worldwide"
Hemodialysis is a medical treatment that cleans a person’s blood when their kidneys can no longer do the job, by routing blood through a machine that filters out waste, excess fluid and adjusts salt levels—think of it as an external, mechanical kidney. It matters to investors because it drives demand for specialized machines, replacement filters, clinics, trained staff and related drugs, and is sensitive to reimbursement rules, treatment volumes and advances that can change costs or market share.
forward-looking statements regulatory
"Certain statements in this press release may constitute forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Rockwell Medical (RMTI) announce about its Nasdaq listing?
Rockwell Medical announced that Nasdaq has notified the company it has regained compliance with the $1.00 per share minimum bid price requirement under Listing Rule 5550(a)(2), and that the prior compliance matter is now closed, with its stock continuing to trade on the Nasdaq Capital Market.
How did Rockwell Medical (RMTI) regain compliance with Nasdaq's minimum bid rule?
Rockwell Medical regained compliance because its shares maintained a minimum closing bid price of $1.00 per share or greater from July 1, 2026 through July 15, 2026, satisfying Nasdaq Listing Rule 5550(a)(2) for the required period and leading Nasdaq to formally close the compliance matter.
Is Rockwell Medical (RMTI) still listed on the Nasdaq Capital Market?
Yes. Rockwell Medical states that it is now in full compliance with all Nasdaq continued listing requirements, and that its common stock remains listed and traded on the Nasdaq Capital Market under the ticker symbol RMTI, following resolution of the compliance matter related to the minimum bid price requirement.
What business is Rockwell Medical (RMTI) engaged in?
Rockwell Medical is a healthcare company that develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. Its products support treatment of patients with end-stage kidney disease in outpatient dialysis centers, hospital-based centers, skilled nursing facilities, and in some cases, a patient’s home.
What forward-looking statement cautions does Rockwell Medical (RMTI) highlight?
Rockwell Medical cautions that certain statements are forward-looking statements, including those about benefits of continued listing on the Nasdaq Capital Market and a reverse stock split. These statements rely on current estimates and assumptions and are subject to risks described in its SEC filings.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 20, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices, including zip code)
(248 ) 960-9009
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) | ||||||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On July 16, 2026, Rockwell Medical, Inc. (the "Company") received a written notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ('Nasdaq') indicating that the Company has regained compliance with the minimum $1.00 per share bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). Accordingly, Nasdaq considers the compliance matter closed.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits The following exhibit is being furnished herewith:
EXHIBIT INDEX
| Exhibit No. | Description | |||||||
| 99.1 | Press release dated July 20, 2026 | |||||||
| 104 | Cover Page Interactive Data File, formatted in INline XBRL and included as Exhibit 101. | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ROCKWELL MEDICAL, INC. | ||||||||
| Date: July 20, 2026 | By: | /s/ Mark Strobeck | ||||||
| Mark Strobeck | ||||||||
| Chief Executive Officer | ||||||||
Rockwell Medical Regains Compliance with Nasdaq Listing Requirements
Wixom, Michigan, July 20, 2026 – Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
In regaining compliance under the Listing Rule, the Company's shares maintained a minimum closing bid price of $1.00 per share or greater from July 1, 2026 to July 15, 2026. As a result, Nasdaq has closed the matter.
Rockwell Medical is now in full compliance with all Nasdaq continued listing requirements, and the Company's stock remains listed and traded on the Nasdaq Capital Market under the ticker "RMTI".
About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work® four years in a row (2023-2026) and named Fortune Best Workplaces in Manufacturing & Production™ in 2024 and 2025, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions™. For more information, visit www.rockwellmed.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," “are determined,” “are committed to,” “are on track,” “are resolute in our vision,” "work to," "drive towards," “focused on,” “seeks to” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. There can be no assurance that Rockwell Medical will be able to realize any of the anticipated benefits from the reverse stock split, including maintaining its listing on the Nasdaq Capital Market. Forward looking statements contained herein include statements related to the benefits of continued listing on the Nasdaq Capital Market. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2025, as such
description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.
# # #
CONTACT:
Heather Hunter
(248) 432-1362
IR@RockwellMed.com.